

February 2019

URGENT: Important Drug Warning Letter

Notice to Healthcare Professional Regarding Safety Information That May Be Missing in the Labeling of Alfentanil Injection, USP; Butorphanol Tartrate Injection, USP; Demerol™ (meperidine HCl Injection, USP); Diazepam Injection, USP; Fentanyl Citrate Injection, USP; Hydromorphone Hydrochloride Injection, USP; Lorazepam Injection, USP; Midazolam Injection, USP; Morphine Sulfate Injection, USP; Nalbuphine Hydrochloride Injection; and Sufentanil Citrate Injection, USP

Dear Healthcare Professional:

Hospira, Inc., a Pfizer company (Hospira) is writing to inform you of important updates to safety information that may not be present in the package inserts of the opioid and benzodiazepine products listed above and in Table 1 in the Appendix. These products were distributed starting January 2017. Refer to Table 1 in the Appendix for NDC product information.

Summary of Updated Safety Information: Opioid Products

Package inserts for the following opioid drug products in your possession may not include updated safety labeling (boxed warning) concerning the interaction between opioids and benzodiazepines: **Alfentanil Injection, USP; Butorphanol Tartrate Injection, USP; Demerol™ (meperidine HCl Injection, USP); Fentanyl Citrate Injection, USP; Hydromorphone Hydrochloride Injection, USP; Morphine Sulfate Injection, USP; Nalbuphine Hydrochloride Injection; and Sufentanil Citrate Injection, USP.** The full updated product inserts for each of these products is available at <https://dailymed.nlm.nih.gov/dailymed/> and <https://www.pfizer.com/products-list>.

The boxed warning information for this group of opioid products that may be missing from products in your possession is provided below:

WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma and death [*see Warnings, Drug Interactions (5.X), Drug Interactions (7.X)*].

- Reserve concomitant prescribing of [Product Name] and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedation.

Summary of Updated Safety Information: Benzodiazepine Products

Package inserts for the following benzodiazepine drug products in your possession may not include updated safety labeling (boxed warning) concerning the interactions between opioids and benzodiazepines: **Diazepam Injection, USP; Midazolam Injection, USP; and Lorazepam Injection, USP.** The full updated product inserts for each of these products is available at <https://dailymed.nlm.nih.gov/dailymed/> and <https://www.pfizer.com/products-list>.

The boxed warning information for this group of benzodiazepine products that may be missing from the package inserts for products in your possession is provided below:

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death [see *Warnings, Drug Interactions*].

- Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedation.

All products distributed after June 30, 2019 will include the updated labeling.

Refer to the following websites for the most current labeling for the opioid and benzodiazepine drug products that contains the complete safety instructions for the respective products:

<https://dailymed.nlm.nih.gov/dailymed/> and <https://www.pfizer.com/products-list>.

If you have any medical questions or comments on the information provided in this letter, please contact: Pfizer Medical Information at 1-800-438-1985 (Mon.-Fri. 8 am - 7 pm ET).

If you have any questions regarding product availability please contact Hospira Customer Service at 1-844-646-4398 (Mon.-Fri. 8am-7pm ET) or your Hospira representative.


Reporting Adverse Events

To report adverse events or quality issues, contact Hospira (Pfizer) at 1-800-438-1985.

Adverse events or quality problems experienced with the use of this product may also be reported to the FDA's MedWatch Adverse Event Reporting Program either online, or regular mail, or by fax:

- Complete and submit the report **Online**: www.fda.gov/medwatch/report.htm
- Regular mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

Sincerely,



Eddie G M Power PhD MBA | Vice President, North America Medical Affairs
Hospital Business
Pfizer Biopharmaceuticals Group

APPENDIX

TABLE 1 – Product Information continued

Product Name	NDC	Strength/Dosage Form	Expiry Dating (months)	First date of distribution (MM/DD/YYYY)
Alfentanil Injection, USP	0409-2266-02	1000 mcg/2mL (500 mcg/mL) UNI-AMP™ Ampul	24	5/5/2017
Butorphanol Tartrate Injection, USP	0409-1623-01	1 mg (1 mg/mL) Single-dose Fliptop Vial	24	6/28/2017
Butorphanol Tartrate Injection, USP Novaplus	0409-1626-10	2 mg/mL Single-dose Vial	24	10/23/2017
Butorphanol Tartrate Injection, USP	0409-1626-01	2 mg (2 mg/mL) Single-dose Fliptop Vial	24	8/23/2017
Butorphanol Tartrate Injection, USP	0409-1626-02	4 mg (2 mg/mL) Single-dose Fliptop Vial	24	10/24/2017
Demerol™ (meperidine HCl injection, USP)	0409-1176-30	50 mg/mL Carpuject™ Sterile Cartridge Unit with Luer Lock	24	3/27/2017
Demerol™ (meperidine HCl injection, USP)	0409-1180-69	100 mg/mL Carpuject™ Sterile Cartridge Unit with Luer Lock	24	4/4/2017
Demerol™ (meperidine HCl injection, USP)	0409-1256-01	10 mg/mL UNI-AMP™ unit dose pak	24	9/27/2017
Demerol™ (meperidine HCl injection, USP)	0409-1254-01	75 mg/1.5 mL (50 mg/mL) UNI-AMP™ unit dose pak	24	9/29/2017
Demerol™ (meperidine HCl injection, USP)	0409-1255-02	100 mg/2 mL (50 mg/mL) UNI-AMP™ unit dose pak	24	9/27/2017
Demerol™ (meperidine HCl injection, USP)	0409-1203-01	25 mg/0.5 mL UNI-AMP™ unit dose pak	24	12/22/2017
Demerol™ (meperidine HCl injection, USP)	0409-1253-01	50 mg/mL UNI-AMP™ unit dose pak	24	8/12/2017
Demerol™ (meperidine HCl injection, USP)	0409-1178-30	50 mg/mL Carpuject™ Sterile Cartridge Unit with Luer Lock	24	4/16/2017

APPENDIX

TABLE 1 – Product Information continued

Product Name	NDC	Strength/Dosage Form	Expiry Dating (months)	First date of distribution (MM/DD/YYYY)
Diazepam Injection, USP	0409-1273-32	10 mg/2 mL (5 mg/mL) Carpuject™ Sterile Cartridge Unit with Luer Lock	18	11/15/2018
Diazepam Injection, USP Novaplus	0409-3213-10	50 mg/10 mL (5 mg/mL) Multiple-dose Vial	24	10/18/2017
Diazepam Injection, USP	0409-3213-12	50 mg/10 mL (5 mg/mL) Multiple-dose Vial	24	6/12/2017
Fentanyl Citrate Injection, USP	0409-9093-32	100 mcg Fentanyl/2mL (50 mcg/mL) Single-dose Ampul	24	4/10/2017
Fentanyl Citrate Injection, USP Novaplus	0409-9093-11	100 mcg Fentanyl/2 mL (50 mcg/mL) Single-dose Ampul	24	4/10/2017
Fentanyl Citrate Injection, USP	0409-9093-35	250 mcg Fentanyl/5 mL (50 mcg/mL) Single-dose Ampul	24	4/3/2017
Fentanyl Citrate Inj., USP	0409-9094-22	100 mcg Fentanyl/2 mL (50 mcg/mL) Single-dose Fliptop Vial	18	9/13/2017
Fentanyl Citrate Injection, USP Novaplus	0409-9094-11	100 mcg Fentanyl/2 mL (50 mcg/mL) Single-dose Fliptop Vial	18	12/13/2017
Fentanyl Citrate Injection, USP	0409-9094-61	2500 mcg Fentanyl/50 mL (50 mcg/mL) Single-dose Vial	24	6/2/2017
Fentanyl Citrate Injection, USP	0409-9094-31	1000 mcg Fentanyl/20 mL (50 mcg/mL) Single-dose Vial	24	6/19/2017
Fentanyl Citrate Inj., USP	0409-9094-28	500 mcg Fentanyl/10 mL (50 mcg/mL) Single-dose Vial	24	11/28/2017
Fentanyl Citrate Injection, USP	0409-9094-25	250 mcg Fentanyl/5 mL (50 mcg/mL) Single-dose Vial	18	10/11/2017
Hydromorphone Hydrochloride Injection, USP	0409-1283-05	0.5 mg/0.5 mL iSecure™ Syringe	24	1/16/2017

APPENDIX

TABLE 1 – Product Information continued

Product Name	NDC	Strength/Dosage Form	Expiry Dating (months)	First date of distribution (MM/DD/YYYY)
Hydromorphone Hydrochloride Injection, USP	0409-1283-10	1 mg/mL, iSecure™ Syringe	24	2/8/2017
Hydromorphone Hydrochloride Injection, USP	0409-1312-10	2 mg/mL, iSecure™ Syringe	24	2/6/2017
Hydromorphone Hydrochloride Injection, USP	0409-1312-30	2 mg/mL Carpuject™ Sterile Cartridge Unit with Luer Lock	24	4/2/2017
Hydromorphone Hydrochloride Injection, USP	0409-2634-01	10 mg/mL, Single Dose Vial	24	06/27/2018
Hydromorphone Hydrochloride Injection, USP	0409-2634-05	50 mg/5 mL (10 mg/mL) Single Dose Vial	24	4/19/2017
Hydromorphone Hydrochloride Injection, USP	0409-2634-50	500 mg/50 mL, (10 mg/50 mL) Single Dose Vial	24	04/05/2017
Hydromorphone Hydrochloride Injection, USP	0409-3365-01	2 mg/mL, Single-use Vial	24	4/4/2017
Hydromorphone Hydrochloride Injection, USP	0409-2634-01	10 mg/mL, Single Dose Vial	24	03/17/2017
Lorazepam Injection, USP	0409-1985-30	2 mg/mL Carpuject™ Sterile Cartridge Unit with Luer Lock	24	6/25/2017
Midazolam Injection, USP	0409-2306-12	2 mg/2 mL (1 mg/mL) Preservative Free iSecure™ Syringe	24	6/27/2017
Midazolam Injection, USP	0409-2307-60	5 mg base/mL, Preservative Free, Carpuject™ Sterile Cartridge Unit with Luer Lock	24	10/5/2017
Midazolam Injection, USP	0409-2305-17	2 mg/2 mL (1 mg/mL) Preservative-Free Single-dose Fliptop Vial	24	5/24/2017
Midazolam Injection, USP	0409-2305-21	2 mg/2 mL (1 mg/mL) Preservative-Free Single-dose Fliptop Vial	24	4/24/2017
Midazolam Injection, USP Novaplus	0409-2305-50	5 mg/5 mL Preservative-Free Single-dose Fliptop Vial	24	9/14/2017

APPENDIX

TABLE 1 – Product Information continued

Product Name	NDC	Strength/Dosage Form	Expiry Dating (months)	First date of distribution (MM/DD/YYYY)
Midazolam Injection, USP	0409-2305-05	5 mg/5 mL (1 mg/mL) Preservative-Free Single-dose Fliptop Vial	24	10/12/2017
Midazolam Injection, USP Novaplus	0409-2308-49	5 mg/mL Preservative-Free Single-dose Fliptop Vial	24	2/26/2018
Midazolam Injection, USP Novaplus	0409-2308-50	10 mg/2 mL (5 mg/mL) Preservative-Free Single-dose Fliptop Vial	24	3/1/2018
Midazolam Injection, USP	0409-2308-01	5 mg/mL Preservative-Free Single-dose Fliptop Vial	24	6/26/2017
Midazolam Injection, USP	0409-2308-02	10 mg/2 mL (5 mg/mL) Preservative-Free Single-dose Fliptop Vial	24	10/16/2017
Midazolam Injection, USP	0409-2596-03	25 mg/5 mL (5mg/mL) Fliptop Vial	24	3/7/2018
Midazolam Injection, USP Novaplus	0409-2596-52	25 mg/5 mL (5mg/mL) Fliptop Vial	24	5/17/2018
Midazolam Injection, USP	0409-2596-05	50 mg/10 mL (5mg/mL) Fliptop Vial	24	3/12/2018
Morphine Sulfate Injection, USP	0409-1890-11	2 mg/mL, iSecure™ Syringe	24	5/22/2017
Morphine Sulfate Injection, USP	0409-1892-11	8 mg/mL, iSecure™ Syringe	24	5/19/2017
Morphine Sulfate Injection, USP	0409-1891-01	4 mg/mL, Carpuject™ Sterile Cartridge Unit with Luer Lock	24	8/17/2017
Morphine Sulfate Injection, USP	0409-1893-01	10 mg/mL, Carpuject™ Sterile Cartridge Unit with Luer Lock	24	6/25/2017
Morphine Sulfate Injection, USP	0409-1890-01	2 mg/mL, Carpuject™ Sterile Cartridge Unit with Luer Lock	24	5/4/2017
Nalbuphine Hydrochloride Injection	0409-1463-01	10 mg/mL Single-dose Ampul	18	12/12/2017

APPENDIX

TABLE 1 – Product Information continued

Product Name	NDC	Strength/Dosage Form	Expiry Dating (months)	First date of distribution (MM/DD/YYYY)
Nalbuphine Hydrochloride Injection	0409-1463-49	10 mg/mL Glass Ampul, Single Dose	18	12/12/2017
Nalbuphine Hydrochloride Injection	0409-1464-01	10 mg/mL Multi-dose Fliptop Vial	18	3/22/2018
Nalbuphine Hydrochloride Injection	0409-1465-01	20 mg Single-dose Ampul	18	7/10/2018
Nalbuphine Hydrochloride Injection	0409-1467-01	20 mg/mL Multi-dose Fliptop Vial	18	3/22/2018
Sufentanil Citrate Inj., USP	0409-3382-21	50 mcg/mL Preservative Free, Fliptop Vial	18	10/30/2017
Sufentanil Citrate Inj., USP	0409-3382-22	100 mcg/2 mL (50 mcg/mL) Preservative Free, Fliptop Vial	18	4/25/2018
Sufentanil Citrate Inj., USP	0409-3382-25	250 mcg/5 mL (50 mcg/mL) Preservative Free, Fliptop Vial	18	1/23/2018


STERICYCLE
(800) 668-4391
2670 EXECUTIVE DR SUITE A
INDIANAPOLIS IN 46241

LTR 1 OF 1

DEAR HEALTHCARE PROVIDER

SHIP N/A
TO: ANY BUSINESS NAME
ANY STREET

ANY CITY XX 12345




NY 122 9-02

SAMPLE

UPS GROUND

TRACKING: 1Z A0Y 770 03 3393 5882



BILLING: P/P

N60059005D4459-1

URC09.5A 01/2019

URGENT: IMPORTANT DRUG WARNING LETTER

